Plans to bring drug approval processes online

This would enable companies to apply online for approval of their products and also upload required documents

Sushmi Dey New Delhi
Last Updated : Jun 03 2014 | 12:23 AM IST
The country's top regulatory agency in the health sector will follow the Narendra Modi mantra of e-governance to bring more transparency and accountability while reducing red tape in clinical trials, drug approvals as well as manufacturing licences. The office of Drugs Controller General of India (DCGI) is preparing a plan to go online with all approval-related processes, etc, an official said.

This would enable companies to apply online for approval of their products and also upload required documents. Companies will be able to track their pleas on a daily basis, the official said.

E-governance will help the regulator and government maintain data related to drug approvals and clinical trials. Recently, the regulator and the health and family welfare ministry were rapped by the Supreme Court for lack of data management and monitoring in clinical trials and deaths that occurred during these.

The move is also in line with the key areas identified by health minister Harsh Vardhan. After the new government formation at the Centre early last week, Vardhan had said he would move fast to put in place e-governance systems in all government-to-citizen and government-to-business interfaces under the ministry. "Accountability standards will be fixed at the highest level and corruption will be checked at source with transparent systems."

The official said the minister in his first briefing had given instructions to follow e-governance model. He added the regulator's office was studying the models of US Food and Drug Administration, UK's Medicines and Healthcare Products Regulatory Agency and Canada drug regulator.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Jun 03 2014 | 12:03 AM IST

Next Story